Edaravone
Brand name: Radicava Ors
Rank #136 of 500 drugs by total cost
$119.6M
Total Cost
8,588
Total Claims
$119.6M
Total Cost
186
Prescribers
$14K
Cost per Claim
727
Beneficiaries
8,610
30-Day Fills
$643K
Avg Cost/Provider
46
Avg Claims/Provider
About Edaravone
Edaravone (sold as Radicava Ors) was prescribed 8,588 times by 186 Medicare Part D providers in 2023, costing the program $119.6M. At $14K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 133 | Brimonidine Tartrate/Timolol (Brimonidine Tartrate-Timolol) | $122.0M | 361,001 |
| 134 | Olaparib (Lynparza) | $121.1M | 8,744 |
| 135 | Empagliflozin/Metformin Hcl (Synjardy Xr) | $119.7M | 121,366 |
| 136 | Edaravone (Radicava Ors) | $119.6M | 8,588 |
| 137 | Insulin Regular, Human (Afrezza) | $119.4M | 143,017 |
| 138 | Ezetimibe (Ezetimibe) | $118.1M | 2,859,001 |
| 139 | Ambrisentan (Ambrisentan) | $117.7M | 23,927 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology